Search Results
Université Claude Bernard Lyon 1, Villeurbanne, France
Centre de Références des IOA Complexes de Lyon, CRIOAc Lyon, Lyon, France
StaPath team, Centre International de Recherche en Infectiologie, CIRI, Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1, Lyon, France
Education and Clinical Officer of the ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)
Search for other papers by Tristan Ferry in
Google Scholar
PubMed
Department of Development and Regeneration, KU Leuven, Oude Markt 13, Leuven, Belgium
Search for other papers by Jolien Onsea in
Google Scholar
PubMed
Search for other papers by Tiphaine Roussel-Gaillard in
Google Scholar
PubMed
Search for other papers by Cécile Batailler in
Google Scholar
PubMed
Search for other papers by Thomas Fintan Moriarty in
Google Scholar
PubMed
Department of Development and Regeneration, KU Leuven, Oude Markt 13, Leuven, Belgium
Search for other papers by Willem-Jan Metsemakers in
Google Scholar
PubMed
-
The treatment of musculoskeletal infections (MSIs), including periprosthetic joint infection (PJI) and fracture-related infection (FRI), is often complicated by biofilm-related challenges necessitating multiple revision surgeries and incurring substantial costs.
-
The emergence of antimicrobial resistance (AMR) adds to the complexity of the problem, leading to increased morbidity and healthcare expenses.
-
There is an urgent need for novel antibacterial strategies, with the World Health Organization endorsing non-traditional approaches like bacteriophage (phage) therapy.
-
Phage therapy, involving the targeted application of lytic potent phages, shows promise in the treatment of MSIs.
-
Although historical clinical trials and recent case studies present significant milestones in the evolution of phage therapy over the past century, challenges persist, including variability in study designs, administration protocols and phage selection. Efforts to enhance treatment efficacy consist of personalized phage therapy and combination with antibiotics.
-
Future perspectives entail addressing regulatory barriers, standardizing treatment protocols, and conducting high-quality clinical trials to establish phage therapy’s efficacy for the treatment of MSIs.
-
Initiatives like the PHAGEFORCE study and the PHAGEinLYON Clinic programme aim to streamline phage therapy, facilitating personalized treatment approaches and systematic data collection to advance its clinical utility in these challenging infections.
